Drug intelligence / Profile preview

cycloprodigiosin hydrochloride

Development stage
Preclinical
Modality
Small Molecules
01

Overview

Cycloprodigiosin hydrochloride is a **stable red fluorescent pigment** isolated from the marine bacterium Pseudoalteromonas denitrificans and related species. It belongs to the prodigiosin family of **tripyrrole alkaloids** and is characterized by a cyclized prodiginine structure. Cycloprodigiosin hydrochloride exhibits **potent antimalarial activity**—with in vitro nanomolar efficacy against Plasmodium falciparum, surpassing chloroquine—and retains activity in vivo. It has also demonstrated **selective anticancer effects** in vitro against various cancer cell lines, as well as immunosuppressive and pro-apoptotic effects on T cells. Its biological activities are thought to arise from its ability to bind and transport ions across membranes and interaction with targets such as B-cell lymphoma 2 (Bcl-2) proteins, though its exact mechanism of action remains incompletely defined[1][2][3][5].

Other names
cPrG·HClcPrG*HClcycloprodigiosin·HCl
02

Targets

H+-PPase (H+-translocating pyrophosphatase)OAR (Octopamine receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)V-ATPase (Vacuolar-type H+-ATPase)PfLDH (Plasmodium falciparum lactate dehydrogenase)

Beyond the preview

Go deeper on cycloprodigiosin hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cycloprodigiosin hydrochloride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call